X

Trial Profile

A phase 2 trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vidofludimus calcium (Primary)
Indications Post acute COVID 19 syndrome
Focus Therapeutic Use
Acronyms RAPID_REVIVE

Most Recent Events

13 Sep 2024 New trial record
04 Sep 2024 According to an Immunic media release, the first patient has been dosed in this trial. The investigator initiated trial is led by Prof. Dr. Vehreschild and sponsored by the Goethe University Frankfurt, which received trial funding via a grant from the German Federal Ministry of Education and Research (BMBF). The trial plans to enroll patients in 11 sites in Germany.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com